HLS Therapeutics Inc Share Price Toronto S.E.
Equities
AM
CA05328X1015
Pharmaceuticals
Sales 2024 * | 59.65M 81.54M 4.98B | Sales 2025 * | 72.37M 98.93M 6.04B | Capitalization | 91.72M 125M 7.66B |
---|---|---|---|---|---|
Net income 2024 * | -20M -27.34M -1.67B | Net income 2025 * | -17M -23.24M -1.42B | EV / Sales 2024 * | 1.54 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.27 x |
P/E ratio 2024 * |
-4.43
x | P/E ratio 2025 * |
-7.99
x | Employees | - |
Yield 2024 * |
5.15% | Yield 2025 * |
-
| Free-Float | 99.51% |
Latest transcript on HLS Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Craig Millian
CEO | Chief Executive Officer | 56 | 01/23/01 |
John Hanna
DFI | Director of Finance/CFO | - | 22/23/22 |
Ryan Lennox
CMP | Compliance Officer | 43 | 07/18/07 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Welborn
CHM | Chairman | 46 | 18/21/18 |
Laura Brege
BRD | Director/Board Member | 66 | 21/19/21 |
John Hanna
DFI | Director of Finance/CFO | - | 22/23/22 |
1st Jan change | Capi. | |
---|---|---|
+20.94% | 72.78B | |
-1.26% | 24.24B | |
+8.25% | 8.38B | |
+5.13% | 8.59B | |
-19.42% | 8.09B | |
+5.56% | 4.81B | |
+16.83% | 4.32B | |
-1.83% | 4.05B | |
-1.65% | 3.93B |